Trial Profile
Effects of Bronchodilatation With Salmeterol on the Autonomic Nervous System
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Oct 2023
Price :
$35
*
At a glance
- Drugs Salmeterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Acronyms ESAN
- Sponsors GlaxoSmithKline; GSK
- 03 Feb 2014 Actual patient number changed from 34 to 32 as reported by ClinicalTrials.gov record.
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.